EBS Emergent BioSolutions Inc.
Stock · NYSE · United States · Healthcare · US29089Q1058
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Emergent BioSolutions Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
6.06 USD
+3.59%
52-week range
4.36 – 14.06
Dividend yield—
Market cap311.6M
NowoTrade score
26 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:53. Information, not advice.
Results
Next results
25 Feb 2027
in 109 days · 16:00 · estimate -0.11
Last results
-0.36 vs -0.39 estimated
02 Nov 2026 · Beat +8.0%
Beat the estimate
9 of 12
3 missed · 0 in line · 3 beats in a row
Average surprise
+183.4%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 16:00 | -0.11 | — | — | Upcoming |
| 02 Nov 2026 16:00 | -0.39 | -0.36 | +8.0% | Beat |
| 05 Aug 2026 16:00 | 0.11 | 0.60 | +445.5% | Beat |
| 30 Apr 2026 16:00 | -0.25 | 0.21 | +184.0% | Beat |
| 26 Feb 2026 16:00 | 0.11 | -0.43 | -490.9% | Miss |
| 29 Oct 2025 16:00 | -0.12 | 1.06 | +984.2% | Beat |
| 06 Aug 2025 16:00 | -0.49 | 0.16 | +132.7% | Beat |
| 07 May 2025 16:00 | 0.44 | 0.71 | +61.4% | Beat |
| 03 Mar 2025 16:00 | -0.50 | 0.05 | +110.1% | Beat |
| 06 Nov 2024 16:00 | 0.14 | 1.37 | +874.5% | Beat |
| 06 Aug 2024 16:00 | -0.97 | -2.32 | -139.6% | Miss |
| 01 May 2024 16:00 | -0.83 | 0.59 | +171.1% | Beat |
| 06 Mar 2024 16:00 | -0.32 | -0.77 | -140.8% | Miss |
| 11 Dec 2023 07:00 | -0.54 | -5.08 | -840.7% | Miss |
| 08 Aug 2023 16:00 | -0.62 | -1.06 | -69.6% | Miss |
| 09 May 2023 16:00 | -1.34 | -3.17 | -136.0% | Miss |
| 27 Feb 2023 16:00 | -0.06 | -0.31 | -389.5% | Miss |
| 08 Nov 2022 16:00 | -0.13 | -1.27 | -882.2% | Miss |
| 01 Aug 2022 16:00 | 0.40 | -0.86 | -317.7% | Miss |
| 28 Apr 2022 16:00 | 0.13 | 0.18 | +43.6% | Beat |
| 24 Feb 2022 16:00 | 4.42 | 4.50 | +1.9% | Beat |
| 04 Nov 2021 16:00 | 2.28 | -0.36 | -115.8% | Miss |
| 29 Jul 2021 16:00 | 1.56 | 0.33 | -78.9% | Miss |
| 29 Apr 2021 16:00 | 1.17 | 1.53 | +31.0% | Beat |
| 18 Feb 2021 16:00 | 3.41 | 3.67 | +7.7% | Beat |
| 05 Nov 2020 16:00 | 2.15 | 2.19 | +2.0% | Beat |
| 30 Jul 2020 16:00 | 0.66 | 1.98 | +202.3% | Beat |
| 30 Apr 2020 17:00 | -0.01 | 0.01 | +207.0% | Beat |
| 20 Feb 2020 16:00 | 1.73 | 1.57 | -9.4% | Miss |
| 06 Nov 2019 16:00 | 0.90 | 1.21 | +34.1% | Beat |
| 01 Aug 2019 16:00 | 0.18 | 0.12 | -34.7% | Miss |
| 02 May 2019 16:00 | 0.18 | -0.13 | -171.1% | Miss |
| 21 Feb 2019 16:00 | 0.65 | 0.75 | +14.8% | Beat |
| 01 Nov 2018 16:00 | 0.61 | 0.55 | -9.6% | Miss |
| 02 Aug 2018 16:00 | 0.93 | 1.07 | +15.7% | Beat |
| 03 May 2018 16:00 | 0.17 | -0.03 | -117.7% | Miss |
| 22 Feb 2018 16:00 | 0.70 | 0.74 | +6.0% | Beat |
| 02 Nov 2017 16:00 | 0.41 | 0.73 | +77.2% | Beat |
| 03 Aug 2017 16:00 | 0.26 | 0.13 | -49.2% | Miss |
| 04 May 2017 17:00 | 0.31 | 0.29 | -5.7% | Miss |
| 23 Feb 2017 16:00 | 0.61 | 0.74 | +20.8% | Beat |
| 07 Nov 2016 16:00 | 0.38 | 0.58 | +54.7% | Beat |
| 04 Aug 2016 16:00 | -0.17 | -0.18 | -4.4% | Miss |
| 05 May 2016 16:00 | -0.12 | 0.16 | +237.1% | Beat |
| 25 Feb 2016 16:00 | 0.70 | 0.78 | +11.4% | Beat |
| 05 Nov 2015 16:00 | 0.54 | 0.83 | +53.7% | Beat |
| 06 Aug 2015 07:00 | 0.18 | 0.36 | +103.8% | Beat |
| 07 May 2015 16:00 | -0.45 | -0.50 | -10.3% | Miss |
| 05 Mar 2015 16:00 | 0.69 | 0.75 | +9.1% | Beat |
| 06 Nov 2014 16:00 | 0.37 | 0.54 | +45.1% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 705.2M | -30.4% | 52.6M | 7.5% | 0.93 | +125.8% | 156.8M |
| 2024 | 1B | -0.9% | -190.6M | -18.8% | -3.60 | +75.8% | 35.8M |
| 2023 | 1B | -4.9% | -760.5M | -74.3% | -14.85 | -232.2% | -257.9M |
| 2022 | 1.1B | — | -211.6M | -19.7% | -4.47 | — | -149.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Sep 2022 | 23.66 | 25.49 | 20.06 | 20.99 | -12.61% | 13,293,600 | |
| Aug 2022 | 34.61 | 35.26 | 23.65 | 24.02 | -30.66% | 16,516,000 | |
| Jul 2022 | 31.05 | 36.14 | 29.06 | 34.64 | +11.60% | 10,392,900 | |
| Jun 2022 | 32.71 | 33.15 | 26.85 | 31.04 | -5.83% | 12,851,300 | |
| May 2022 | 32.01 | 40.45 | 27.61 | 32.96 | +1.79% | 23,087,100 | |
| Apr 2022 | 41.53 | 44.04 | 31.41 | 32.38 | -21.14% | 11,471,400 | |
| Mar 2022 | 40.63 | 45.14 | 36.20 | 41.06 | -0.77% | 13,939,600 | |
| Feb 2022 | 46.83 | 47.71 | 38.75 | 41.38 | -11.58% | 10,410,000 | |
| Jan 2022 | 43.79 | 52.28 | 43.40 | 46.80 | +7.66% | 12,379,400 | |
| Dec 2021 | 44.08 | 46.53 | 39.35 | 43.47 | -1.47% | 18,986,800 | |
| Nov 2021 | 33.42 | 45.06 | 32.02 | 44.12 | — | 25,951,700 |
Page 3 of 3
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Emergent BioSolutions: A Turnaround Still Waiting For Consistent Execution (opens in a new tab) SeekingAlpha · 06 Nov 2026 07:30
- Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs on ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 07:01
- Emergent BioSolutions Inc. Receives $22.3 million Delivery Order Modification to Supply BioThrax (opens in a new tab) Fintel · 05 Nov 2026 02:48
- Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War (opens in a new tab) 04 Nov 2026 21:05
- Emergent BioSolutions Awarded $22.3M Contract Modification To Provide BioThrax To U.S. Department Of War (opens in a new tab) Benzinga · 04 Nov 2026 17:12
- Emergent BioSolutions Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 03 Nov 2026 13:30
- Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors (opens in a new tab) Motley Fool · 03 Nov 2026 12:02
- Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 05:28
- Emergent Biosolutions: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 03 Nov 2026 04:25
- Emergent BioSolutions Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 03 Nov 2026 02:00
- Emergent BioSolutions (NYSE:EBS) Shares Fall as Q3 2026 Revenue Misses and Adjusted EBITDA Turns Negative (opens in a new tab) ChartMill · 02 Nov 2026 23:19
- Emergent Biosolutions Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 02 Nov 2026 23:13
- Emergent BioSolutions Inc. (EBS) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 02 Nov 2026 21:38
- Emergent Biosolutions Reports Third Quarter 2026 Financial Results (opens in a new tab) 02 Nov 2026 21:05
- Emergent BioSolutions Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 02 Nov 2026 18:35
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 5.85 USD
- Market cap
- 311.6M
- Exchange
- NYSE
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 0.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 11.5 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 15.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Thin interest cover: operating profit is only 1.9× the interest
- Revenue has fallen two years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 5.79× | Good | 14.89× |
| Price / book | 0.99× | Good | 3.8× |
| Price / sales | 0.48× | Good | 3.19× |
| EV / EBITDA | 5.17× | Good | 12.61× |
| Free cash flow yield | 63.1% | Good | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 43.4% | Good | 58.6% |
| Operating margin | -23.5% | Weak | 7.6% |
| Net margin | -40.2% | Weak | 2.7% |
| Return on equity | -58.2% | Weak | 5.7% |
| Return on assets | 1.9% | Weak | 3.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | -13.1% | Weak | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 1.64× | Weak | 0.48× |
| Net debt / EBITDA | 2.69× | Fair | 1.6× |
| Interest cover | 1.89× | Weak | 2.65× |
| Current ratio | 4.58× | Good | 2.36× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow EBS and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.